Literature DB >> 23809146

Mechanism of dual specificity kinase activity of DYRK1A.

Agnes Walte1, Katharina Rüben, Ruth Birner-Gruenberger, Christian Preisinger, Simone Bamberg-Lemper, Nikolaus Hilz, Franz Bracher, Walter Becker.   

Abstract

The function of many protein kinases is controlled by the phosphorylation of a critical tyrosine residue in the activation loop. Dual specificity tyrosine-phosphorylation-regulated kinases (DYRKs) autophosphorylate on this tyrosine residue but phosphorylate substrates on aliphatic amino acids. This study addresses the mechanism of dual specificity kinase activity in DYRK1A and related kinases. Tyrosine autophosphorylation of DYRK1A occurred rapidly during in vitro translation and did not depend on the non-catalytic domains or other proteins. Expression in bacteria as well as in mammalian cells revealed that tyrosine kinase activity of DYRK1A is not restricted to the co-translational autophosphorylation in the activation loop. Moreover, mature DYRK1A was still capable of tyrosine autophosphorylation. Point mutants of DYRK1A and DYRK2 lacking the activation loop tyrosine showed enhanced tyrosine kinase activity. A series of structurally diverse DYRK1A inhibitors was used to pharmacologically distinguish different conformational states of the catalytic domain that are hypothesized to account for the dual specificity kinase activity. All tested compounds inhibited substrate phosphorylation with higher potency than autophosphorylation but none of the tested inhibitors differentially inhibited threonine and tyrosine kinase activity. Finally, the related cyclin-dependent kinase-like kinases (CLKs), which lack the activation loop tyrosine, autophosphorylated on tyrosine both in vitro and in living cells. We propose a model of DYRK autoactivation in which tyrosine autophosphorylation in the activation loop stabilizes a conformation of the catalytic domain with enhanced serine/threonine kinase activity without disabling tyrosine phosphorylation. The mechanism of dual specificity kinase activity probably applies to related serine/threonine kinases that depend on tyrosine autophosphorylation for maturation.
© 2013 FEBS.

Entities:  

Keywords:  DYRK; HIPK2; iodotubercidin; kinase inhibitors; tyrosine autophosphorylation

Mesh:

Substances:

Year:  2013        PMID: 23809146     DOI: 10.1111/febs.12411

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  29 in total

1.  Ssp2 Binding Activates the Smk1 Mitogen-Activated Protein Kinase.

Authors:  Chong Wai Tio; Gregory Omerza; Timothy Phillips; Hua Jane Lou; Benjamin E Turk; Edward Winter
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

2.  Effects of Y361-auto-phosphorylation on structural plasticity of the HIPK2 kinase domain.

Authors:  Antonella Scaglione; Laura Monteonofrio; Giacomo Parisi; Cristina Cecchetti; Francesca Siepi; Cinzia Rinaldo; Alessandra Giorgi; Daniela Verzili; Carlotta Zamparelli; Carmelinda Savino; Silvia Soddu; Beatrice Vallone; Linda Celeste Montemiglio
Journal:  Protein Sci       Date:  2017-12-28       Impact factor: 6.725

3.  Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.

Authors:  Adolfo Quiñones-Lombraña; Javier G Blanco
Journal:  Exp Mol Pathol       Date:  2019-06-12       Impact factor: 3.362

4.  DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.

Authors:  Jianling Ji; Hane Lee; Bob Argiropoulos; Naghmeh Dorrani; John Mann; Julian A Martinez-Agosto; Natalia Gomez-Ospina; Natalie Gallant; Jonathan A Bernstein; Louanne Hudgins; Leah Slattery; Bertrand Isidor; Cédric Le Caignec; Albert David; Ewa Obersztyn; Barbara Wiśniowiecka-Kowalnik; Michelle Fox; Joshua L Deignan; Eric Vilain; Emily Hendricks; Margaret Horton Harr; Sarah E Noon; Jessi R Jackson; Alisha Wilkens; Ghayda Mirzaa; Noriko Salamon; Jeff Abramson; Elaine H Zackai; Ian Krantz; A Micheil Innes; Stanley F Nelson; Wayne W Grody; Fabiola Quintero-Rivera
Journal:  Eur J Hum Genet       Date:  2015-05-06       Impact factor: 4.246

5.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

6.  Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4/NF-κB P65 Signaling Pathway.

Authors:  Cheng Ju; Yue Wang; Caixia Zang; Hui Liu; Fangyu Yuan; Jingwen Ning; Meiyu Shang; Jingwei Ma; Gen Li; Yang Yang; Xiuqi Bao; Dan Zhang
Journal:  Inflammation       Date:  2022-08-02       Impact factor: 4.657

7.  Selective Macrocyclic Inhibitors of DYRK1A/B.

Authors:  Chelsea E Powell; John M Hatcher; Jie Jiang; Prasanna S Vatsan; Jianwei Che; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2022-03-08       Impact factor: 4.632

Review 8.  DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Authors:  Amina Jamal Laham; Maha Saber-Ayad; Raafat El-Awady
Journal:  Cell Mol Life Sci       Date:  2020-09-01       Impact factor: 9.261

9.  Non-invasive and high-throughput interrogation of exon-specific isoform expression.

Authors:  Dong-Jiunn Jeffery Truong; Teeradon Phlairaharn; Bianca Eßwein; Christoph Gruber; Deniz Tümen; Enikő Baligács; Niklas Armbrust; Francesco Leandro Vaccaro; Eva-Maria Lederer; Eva Magdalena Beck; Julian Geilenkeuser; Simone Göppert; Luisa Krumwiede; Christian Grätz; Gerald Raffl; Dominic Schwarz; Martin Zirngibl; Milica Živanić; Maren Beyer; Johann Dietmar Körner; Tobias Santl; Valentin Evsyukov; Tabea Strauß; Sigrid C Schwarz; Günter U Höglinger; Peter Heutink; Sebastian Doll; Marcus Conrad; Florian Giesert; Wolfgang Wurst; Gil Gregor Westmeyer
Journal:  Nat Cell Biol       Date:  2021-06-03       Impact factor: 28.824

10.  Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (HIPK).

Authors:  Jan van der Laden; Ulf Soppa; Walter Becker
Journal:  Cell Commun Signal       Date:  2015-01-29       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.